

Stahl's Illustrated

Index

- abbreviations, 132. See also symbols
- acamprosate, 50
- acetylcholine-linked agents, 81
- ACR16, 93
- adrenergic receptors. See norepinephrine
- affect meter, 23
- aggression, and symptoms, 7, 28, 116, 124
- agitation, and symptoms, 5–7, 11, 20, 24, 26
- agonist spectrum, and atypical antipsychotics, 88, 90–1
- alpha 2 autoreceptors, 36
- alpha 2 delta ligands, 74–5. See also gabapentin; pregabalin
- amisulpride, 89, 93–4
- AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), 42, 82
- amygdala, 28
- amyotrophic lateral sclerosis (ALS), 72
- anticholinergics, 77, 79
- anticonvulsants, 51, 63, 81. See also carbamazepine; gabapentin; lamotrigine; oxcarbazepine; pregabalin; riluzole; topiramate; valproate; zonisamide
- antidepressants, and mania, 128
- antihypertensives, 97, 99, 103, 105, 107
- antipsychotics. See also atypical antipsychotics
- cardiometabolic risk, 118–19
 - dopamine pathways, 39, 90
 - future compounds, 81–2
 - mechanisms of action as mood stabilizers, 85, 95
 - sedation, 123
 - weight gain, 119
- antisocial personality disorder, 3
- anxiety, 7, 10, 28, 50, 74. See also anxiety disorders
- anxiety disorders, 3, 12, 116
- apathy, and symptoms, 5, 21
- appetite changes, and symptoms of depression, 5, 19, 22. See also eating habits; weight gain or loss
- aripiprazole, 85, 93–5, 106–107, 119, 126
- arousal, and symptoms of mania, 24
- asenapine, 108, 119, 126
- attention-deficit/hyperactivity disorder (ADHD), 116
- atypical antipsychotics. See also antipsychotics; aripiprazole; asenapine; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone
- agonist spectrum, 88
 - bipolar depression, 84
 - dopaminergic functioning, 38, 87–92
 - evidence-based bipolar combinations, 126
 - glutamate release, 43, 86

- as mood stabilizers, 83
 - partial agonists, 88–94
 - sedation, 123–5
- baseline measurements, and management of mood stabilizers, 121
- behavioral therapies, 129
- benzodiazepines, 50, 112–14, 124
- bifeprunox, 93
- biology, and basis of symptoms in bipolar depression, 17. See also neurobiology
- bipolar depression, 8, 10, 67, 84, 89, 114. See also depression
- bipolar disorder. See also mania; mood stabilizers; symptom-based treatment algorithm; treatment; treatment-resistant bipolar disorder
- antidepressants in patients with, 128
 - atypical antipsychotics, 83
 - biological basis of symptoms, 17
 - bipolar spectrum, 15
 - common comorbidities, 12, 116
 - current best treatments for, 112
 - introduction to symptoms and spectrum of, 1
 - lithium and anticonvulsants as mood stabilizers for, 51
 - maintenance pharmacy, 115
 - “mania-minded” versus “depression-minded” treatment of, 111
 - mechanisms of action of antipsychotics in, 85
 - mood charts, 2
 - mood disorders and diagnosis of, 3
 - neurobiology and specific mechanisms of, 29
 - neurotransmission, 47
 - psychotherapy, 129
 - system-based approach to, 131
- bipolar I and bipolar II disorders, symptoms of, 11, 12
- bipolar spectrum, 15
- bipolar storm, 27, 47
- blood pressure, 122
- body mass index, 120–2
- borderline personality disorder, 3, 116
- 140
- Boston bipolar brew, 128
- brain circuits, 17–28. See also neurobiology; neurotransmission and neurotransmitters
- calcium channel blockers, 48–9
- calcium ion channels, 58, 62, 68, 72, 76. See also voltage-sensitive ion channels (VSCCs and VSSCs)
- California careful cocktail, 128
- carbamazepine, 47–9, 62–3, 65–6, 77, 111, 123
- carbonic anhydrase and carbonic anhydrase inhibitors, 49, 76, 77, 79
- cardiometabolic risk, of mood stabilizers, 118–19, 122. See also side effects
- cardiovascular disease, 120
- cariprazine/RGH188, 93–4
- circuits. See brain circuits
- clozapine, 119
- cognitive problems, in mania, 26. See also concentration; executive dysfunction; racing thoughts
- combinations, of drugs, 126–8. See also drug interactions
- comorbidity, of bipolar disorder with other diagnoses, 12, 116
- COMT (catechol-O-methyl transferase), 39
- concentration, and symptoms of depression, 19. See also distractibility
- coping mechanisms, and psychotherapy, 129
- CRF1 antagonists, 81
- cyclothymia, symptoms of, 13
- CYP 1A2 inhibitors and inducers, 73
- CYP 3A4 inhibitors and inducers, 79, 97
- CYP450 1A2 inhibitors and inducers, 103
- CYP450 2D6 inhibitors, 97, 99, 107
- CYP450 3A4 inhibitors and inducers, 97, 107
- DA agonist, 99, 103, 105, 107. See also dopamine partial agonist; D2 partial agonist; D3 partial agonist
- D2 antagonist, 90
- D2 partial agonist, 89–90, 93
- D3 partial agonist, 94

Cambridge University Press

978-0-521-75849-9 - Stahl's Illustrated: Mood Stabilizers

Stephen M. Stahl

Index

[More information](#)

- DAT (dopamine transporter), 39
 d-cyclosporine, 82
 delusions, and symptoms, 7, 28
 depression. See also bipolar depression;
 double depression; major depressive disorder;
 unipolar depression
 brain circuits, 19, 28
 clinical actions of mood stabilizers, 111
 insomnia or hypersomnia, 26
 mood charts, 2, 9
 symptoms of, 5, 7, 19–23
 diabetes, 120–1
 diabetic ketoacidosis (DKA), 121
 diagnosis. See also symptoms
 diagnostic versus nondiagnostic symptoms, 28
 major depressive episode, 5
 manic episode, 6
 misdiagnosis of bipolar disorder, 1, 3
 Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), 5–6, 15
 distractibility, and symptoms, 6–7, 11, 24, 26. See also concentration
 dopamine (DA), and neurotransmission, 20, 23, 38–9, 87, 90. See also neurotransmitters and neurotransmission
 dopamine agonists/antagonists, 39, 82. See also dopamine partial agonist; D2 partial agonist; D3 partial agonist
 dopamine partial agonist (DPA), 112–15
 dosing, of mood stabilizers
 aripiprazole, 107
 carbamazepine, 63
 lamotrigine, 69
 lithium, 55
 olanzapine, 103
 quetiapine, 97
 paliperidone, 101
 riluzole, 73
 risperidone, 99
 topiramate, 77
 valproate, 59
 ziprasidone, 105
 zonisamide, 79
 double depression, 9
 drug interactions
 aripiprazole, 107
 carbamazepine, 63
 lamotrigine, 69
 lithium, 55
 olanzapine, 103
 quetiapine, 97
 paliperidone, 101
 riluzole, 73
 risperidone, 99
 topiramate, 77
 valproate, 59
 ziprasidone, 105
 zonisamide, 79
 dyslipidemia, 121
 dysthymia, 2, 9, 13

 EAAT (excitatory amino acid transporter), 42
 eating disorders, 50
 eating habits, and symptoms, 7, 10. See also appetite changes; weight gain or loss
 educational therapies, 129
 elevated mood, and mania, 6–7, 25
 eslicarbazepine. See oxcarbazepine
 euthymia, 2
 evidence-based bipolar combos, of drugs, 126
 excitation-secretion coupling, 46
 executive dysfunction, and symptoms of depression, 5, 21. See also cognitive problems; concentration; information processing
 extended-release (XR) formulation, of carbamazepine, 62

 family members, roles in diagnosis and monitoring, 8, 117
 fatigue, and symptoms of depression, 5, 19, 21
 fibromyalgia, 74
 fluoxetine, 114
 friends, and diagnosis of unipolar or bipolar depression, 8
 full agonists, 88–9

 GABA (gamma-aminobutyric acid), 40, 48, 50

- gabapentin, 48–50, 74, 111
- genetic factors, and choice of mood stabilizer, 122
- geriatric patients, and depression, 21
- glucocorticoid antagonists, 81
- glutamate, and neurotransmission, 27, 41–3, 47
- glycine agonists, 82
- glycine transporter (GlyT1) inhibitors, 81
- G proteins, 34, 54, 92
- grandiosity, and symptoms of mania, 6–7, 24–5
- guilt, and symptoms of depression, 5, 19, 22
- hallucinations, and symptoms of mania, 7, 28
- hostility, and sedation as therapeutic tool, 124
- hyperactivity, and mania, 26, 28
- hyperinsulinemia, 120
- hyperosmolar hyperglycemic state (HHS), 121
- hypersexuality, and symptoms, 7, 28
- hypomania, 2, 13
- impulsivity, and symptoms, 7, 28, 116
- information processing, 20–1, 38. See also executive dysfunction
- insulin resistance, and psychopharmacologists, 122
- inverse agonists, 89
- irritability, and symptoms, 6–7, 11, 25
- JZP-4, 81
- kainate, 42
- lamotrigine, 47–9, 59, 67–71, 111, 119, 127
- levetiracetam, 48–9, 80, 111
- lifestyle interventions, 121–2
- lithium, 50–1, 54–6, 118–19, 123, 126–7
- l-methylfolate (LMF), 112, 114
- maintenance therapy, for bipolar disorder, 115
- major depressive disorder (MDD), 3, 5, 9, 14. See also depression
- mania. See also bipolar disorder; hypomania; psychotic mania
- antidepressants, 128
 - anti-manic action at VSSCs, 47
 - antipsychotics, 95
 - asenapine, 108
 - atypical antipsychotics, 86–7, 89
 - brain circuits, 24–6, 28
 - carbamazepine, 66
 - clinical actions of mood stabilizers, 111
 - current best treatments for, 113
 - glutamate pathways, 41, 86
 - lithium, 56
 - mood chart, 2
 - partial agonists, 89
 - sedation as therapeutic tool, 124
 - symptoms of, 6–7, 24–6, 28, 50
 - valproate, 57
- “metabolically friendly” mood stabilizers, 119
- metabolic highway, and cardiovascular disease, 120
- metabolic monitoring tool kit, 122
- metabolism, of serotonin, 32
- metabotropic glutamate receptor (mGluR), 42
- mGluR agents, 82
- migraines, and topiramate, 76
- monitoring
- of mood and mood disorders, 2, 117
 - of mood stabilizers, 121
- monoamine(s), and symptoms of depression, 20
- monoamine oxidase (MAO) enzymes, 32, 39
- mood charts, 2, 8–14
- mood disorders. See also anxiety disorders; depression
- comorbidity and treatment of bipolar disorder, 116
 - misdiagnosis of bipolar disorder, 3
 - monitoring of patients with, 117

- mood charts and identification of, 9
- as progressive, 14
- mood lability, and bipolar depression, 10
- mood stabilizers. *See also* anticonvulsants; antipsychotics; dosing; drug interactions; side effects
 - clinical actions, 111
 - combinations of, 126–7
 - dopaminergic pathways, 38
 - future antipsychotics, 81–2
 - glutamate release, 43
 - monitoring and managing, 121
 - neurotransmitters and mechanisms of action, 48–9
 - symptom-based algorithm for, 28, 30, 50
 - voltage-sensitive calcium channels (VSCCs), 45
 - voltage-sensitive sodium channels (VSSCs), 44
- motor retardation, and bipolar depression, 10
- naltrexone, 50
- negative affect, 23
- NET (norepinephrine transporter), 36
- net agonist, 88
- neurobiology. *See also* brain circuits; neurotransmission and neurotransmitters
 - introduction to specific mechanisms in bipolar disorder, 29
 - symptom-based treatment algorithm, 30
 - understanding nature of illness, 17
- neurokinin antagonists, 81
- neuropathic pain, 74
- neurotransmission and neurotransmitters. *See also* brain circuits; dopamine; GABA; glutamate; norepinephrine; serotonin; voltage-sensitive ion channels (VSCCs and VSSCs)
 - agonist spectrum, 88
 - atypical antipsychotics, 96
 - biology of mood stabilizers, 44–5
 - bipolar storm, 27, 47
 - symptom-based treatment algorithm, 30, 50
- nicotine dependence, 116
- NMDA (N-methyl-d-aspartate), 27, 42
- noncompliance, and sedation, 125
- norepinephrine (NE), and neurotransmission, 20, 23, 28, 35–7. *See also* neurotransmitters and neurotransmission
 - norepinephrine and dopamine reuptake inhibitors (NDRIs), 114
 - norquetiapine, 85, 96
 - “not otherwise specified” bipolar disorders (NOS), 15
 - novelty seeking, and symptoms of mania/bipolar spectrum, 7
- olanzapine, 85, 95, 102–103, 114, 119, 125–6
- oral contraceptives, 63, 69, 77
- overactivity, and symptoms, 7
- oxcarbazepine, 47–9, 64–6, 111
- paliperidone, 85, 100–101, 119, 126
- partial agonists, and atypical antipsychotics, 88–94. *See also* dopamine partial agonist; D2 partial agonist; D3 partial agonist
 - peptide-linked agents, 81
- personality disorders. *See* antisocial personality disorder; borderline personality disorder
- phenytoin, 77
- pleasure, and symptoms of depression, 19, 21
- positive affect, 23
- positive allosteric modulators (PAMs), 82
- postsynaptic norepinephrine receptors, 36
- postsynaptic serotonin receptors, 34
- posttest, and CME credit, 145–8
- potassium ion channels, 62, 68, 72
- practice-based bipolar combos, of drugs, 127
- pramipexole, 93–4
- prefrontal cortex (PFC), 28
- pregabalin, 48–50, 74, 111
- presynaptic alpha 2 norepinephrine receptors, 37
- presynaptic serotonin receptors, 33
- progressive, bipolar disorder as, 14
- psychopharmacologists, 122

Cambridge University Press

978-0-521-75849-9 - Stahl's Illustrated: Mood Stabilizers

Stephen M. Stahl

Index

[More information](#)

psychosis and psychotic symptoms, 10, 38, 116, 124. See also schizophrenia
 psychotherapy, 129
 psychotic mania, and atypical antipsychotics, 86–7, 89, 124

quetiapine, 85, 95–7, 119, 125–6

racing thoughts, and symptoms of mania, 6–7, 24–5. See also cognitive problems
 rapid cycling bipolar disorder, 13–14
 recurrence, of manic episodes, 95
 relapse, of bipolar disorder, 98
 RGH188. See cariprazine
 riluzole, 48–9, 71–3, 111
 risk taking, and symptoms, 6–7, 11, 25
 risperidone, 85, 95, 98–9, 119, 125–6
 ropinirole, 93–4

sarcosine, 81

saredutant, 81

sarizotan, 93

schizophrenia, 3, 89, 108

second messenger activation, and partial agonists, 92

sedation, and antipsychotics, 123–5. See also side effects

selective serotonin reuptake inhibitors (SSRIs), 114

self-esteem, and symptoms, 11, 25

serotonin (5HT), and neurotransmission, 20, 31–4, 43. See also neurotransmitters and neurotransmission

serotonin agonist/antagonists, 82

serotonin-dopamine antagonist (SDA), 112–15

serotonin norepinephrine reuptake inhibitors (SNRIs), 114

serotonin transporter (SERT), 32

side effects

aripiprazole, 107

asenapine, 108

carbamazepine, 63

lamotrigine, 69

lithium, 55

olanzapine, 103

paliperidone, 101

psychopharmacologists and prevention of, 122

quetiapine, 97

riluzole, 73

risperidone, 99

topiramate, 77

valproate, 59

ziprasidone, 104, 105

zonisamide, 79

sigma 1 agonists/antagonists, 82

signal propagation, role of VSCCs and VSSCs in regulation of, 46

signal transduction system, 34, 54, 58, 61, 91

silent antagonists, 89

sleep and sleep disturbances

bipolar depression, 10

gabapentin and pregabalin, 74

sedation as therapeutic tool, 124

symptoms of depression, 5, 19–20

symptoms of mania, 6–7, 24, 26

SLV313 and SLV314, 93

sodium ion channels, 68, 72, 76. See also voltage-sensitive ion channels (VSCCs and VSSCs)

somatodendritic autoreceptors, 33

SSR181507, 93

striatum, 28

sublingual formulation, of asenapine, 108

substance abuse and substance abuse disorders, 7, 28, 50, 116

suicidality and suicidal ideation, 5, 10, 19, 22, 56. See also side effects

sulpiride, 89, 93–4

symbols, guides to, 51, 83. See also abbreviations

symptom(s). See also symptom-based treatment algorithm

bipolar depression, 10

bipolar I and bipolar II disorders, 11, 12

brain circuits, 17–18

cyclothymia, 13

depression, 5, 7, 19–23

diagnosis of unipolar versus bipolar

depression, 8, 10

- diagnostic versus nondiagnostic, 28
- dysthymia, 13
- mania, 6–7, 24–26, 28, 50
 - mood stabilizers and matching with, 50
- symptom-based treatment algorithm, for bipolar disorder
 - brain circuits, 28
 - building of treatment plan, 109–10
 - identification of diagnostic and associated symptoms, 1, 4, 7
 - mood stabilizers, 28
 - neurotransmitters, 50
- pharmacologic mechanisms, 53
- synaptic vesicles, 49
- systematic monitoring, 117

- talkative pressured speech, and symptoms of mania, 6–7, 24–5
- Tennessee mood shine, 128
- thought and thinking. *See* cognitive problems; racing thoughts
- thyroid hormones (T3/T4), 112, 114
- topiramate, 47–50, 59, 76–7, 111
- treatment. *See also* mood stabilizers; symptom-based treatment algorithm
 - bipolar depression, 114
 - building of plan for, 109–10
 - common comorbidities, 116
 - current best practices, 112–13
 - maintenance therapy, 115
 - monitoring and managing mood stabilizers, 121
 - psychopharmacologists, 122
 - psychotherapy, 129
 - sedation as therapeutic tool, 124
- treatment portfolio, 110, 112
- treatment-resistant bipolar disorder, 14
- treatment-resistant unipolar depression, 89
- triglycerides (TGs), 121

- unipolar depression, 1, 8, 10, 14, 89. *See also* depression

- valproate, 47–9, 57–61, 69, 77, 111, 118–19, 123, 126–7
- varenicline, 50, 81

- vesicular monoamine transporter 2 (VMAT2), 36, 39
- v-Glu-T (vesicular transporter for glutamate), 42
- violence, and sedation as therapeutic tool, 124
- voltage-sensitive ion channels (VSCCs and VSSCs), 27, 44–7, 49–50, 60, 65, 70, 75. *See also* calcium ion channels; sodium ion channels
- V1B antagonists, 81

- weight gain or loss, as symptoms, 5, 7, 22, 119. *See also* appetite changes; body mass index; eating habits; side effects
- worthlessness, and symptoms of depression, 5, 19, 22

- ziprasidone, 85, 95, 104–105, 119, 126
- zonisamide, 47–50, 78–9, 111